Page last updated: 2024-11-13
deleobuvir
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
deleobuvir: a hepatitis C virus polymerase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 56948249 |
| CHEMBL ID | 2403318 |
| SCHEMBL ID | 900176 |
| SCHEMBL ID | 900174 |
| MeSH ID | M000599048 |
Synonyms (30)
| Synonym |
|---|
| CHEMBL2403318 |
| bi-207127 |
| BMAIGAHXAJEULY-UKTHLTGXSA-N |
| (e)-3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1h-indole-6-carboxamido)cyclobutyl)-1-methyl-1h-benzo[d]imidazol-6-yl)acrylic acid |
| deleobuvir |
| 863884-77-9 |
| (e)-3-(2-(1-(((2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1h-indol-6-yl)carbonyl)amino)cyclobutyl)-1-methyl-1h-benzimidazol-6-yl)-2-propenoic acid |
| 58bu988k90 , |
| 2-propenoic acid, 3-(2-(1-(((2-(5-bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1h-indol-6-yl)carbonyl)amino)cyclobutyl)-1-methyl-1h-benzimidazol-6-yl)-, (2e)- |
| (2e)-3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1h-indole-6-carboxamido)cyclobutyl(-1-methyl-1h-benzimidazol-6-yl)prop-2-enoic acid |
| deleobuvir [usan:inn] |
| bi207127 |
| bi 207127 |
| unii-58bu988k90 |
| deleobuvir [usan] |
| deleobuvir [who-dd] |
| deleobuvir [inn] |
| 1221574-24-8 |
| SCHEMBL900176 |
| SCHEMBL900174 |
| DTXSID40235516 |
| (e)-3-[2-[1-[[[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1h-indol-6-yl]carbonyl]amino]cyclobutyl]-1-methyl-1h-benzimidazol-6-yl]-2-propenoic acid |
| DB14850 |
| Q15708312 |
| (e)-3-[2-[1-[[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methylindole-6-carbonyl]amino]cyclobutyl]-3-methylbenzimidazol-5-yl]prop-2-enoic acid |
| CS-0012113 |
| HY-12634 |
| (e)-3-[2-[1-[[[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1h-indol-6-yl]carbonyl]amino]cyclobutyl]-1-methyl-1h-benzimidazol-6-yl]-2-propenoicacid |
| deleobuvir (bi-207127) |
| AKOS040751520 |
Research Excerpts
Overview
Deleobuvir is a potent inhibitor of the hepatitis C virus nonstructural protein 5B polymerase.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Deleobuvir is a potent inhibitor of the hepatitis C virus nonstructural protein 5B polymerase. " | ( Defining the Role of Gut Bacteria in the Metabolism of Deleobuvir: In Vitro and In Vivo Studies. Johnstone, N; Keith-Luzzi, M; King, I; Li, Y; McCabe, M; Sane, RS; Tweedie, DJ; Whitcher-Johnstone, A; Xu, J, 2015) | 2.11 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The most frequent adverse events in patients with/without cirrhosis were gastrointestinal and skin events, which were mostly mild or moderate in intensity." | ( Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. Angus, P; Asselah, T; Böcher, W; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Manns, M; Mensa, FJ; Müllhaupt, B; Roberts, S; Sabo, JP; Schuchmann, M; Soriano, V; Stern, JO; Stickel, F; Voss, F; Zeuzem, S, 2015) | 0.69 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Deleobuvir had moderate to high clearance, and the half-life of deleobuvir and radioactivity in plasma were ∼ 3 h, indicating that there were no metabolites with half-lives significantly longer than that of the parent." | ( Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor. Chen, LZ; Latli, B; Mandarino, DA; Mao, Y; Philip, E; Ramsden, D; Rowland, L; Sabo, JP; Sane, RS, 2015) | 1.55 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "The drug-drug interaction (DDI) potential of deleobuvir, an hepatitis C virus (HCV) polymerase inhibitor, and its two major metabolites, CD 6168 (formed via reduction by gut bacteria) and deleobuvir-acyl glucuronide (AG), was assessed in vitro." | ( Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes. Cooper, C; Ramsden, D; Rowland, L; Sabo, JP; Sane, RS; Ting, N; Tweedie, DJ; Whitcher-Johnstone, A, 2016) | 0.92 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RNA-directed RNA polymerase | IC50 (µMol) | 0.0190 | 0.0190 | 2.5279 | 8.8000 | AID1787869 | |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RNA-directed RNA polymerase | EC50 (µMol) | 0.0170 | 0.0018 | 0.2348 | 2.8000 | AID1787870; AID1787871 | |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Ceullar Components (1)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (19)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1070917 | Inhibition of poliovirus RdRp | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127). |
| AID1070915 | Antiviral activity against Hepatitis C virus genotype 1b infected in human S22.3 cells assessed as inhibition of viral RNA replication by real-time RT-PCR analysis | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127). |
| AID758860 | Antiviral activity against Hepatitis C virus genotype 3 | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 | Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. |
| AID1070920 | Inhibition of DNA polymerase-gamma (unknown origin) | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127). |
| AID1070914 | Inhibition of DdRp-2 (unknown origin) | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127). |
| AID758859 | Antiviral activity against Hepatitis C virus genotype 2 | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 | Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. |
| AID758856 | Antiviral activity against Hepatitis C virus genotype 4 | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 | Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. |
| AID1073854 | Antiviral activity against Hepatitis C virus genotype 1a by cell-based assay | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. |
| AID758862 | Antiviral activity against Hepatitis C virus genotype 1a | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 | Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. |
| AID1070916 | Antiviral activity against Hepatitis C virus genotype 1a infected in human 129-S.16 cells assessed as inhibition of viral RNA replication by real-time RT-PCR analysis | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127). |
| AID1070913 | Inhibition of DNA polymerase-beta (unknown origin) | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127). |
| AID1073855 | Antiviral activity against Hepatitis C virus genotype 1b by cell-based assay | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. |
| AID1450606 | In vivo drug metabolism in human assessed as 3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)propanoic acid metabolite formation in blood at 800 mg,po administered as single d | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8). |
| AID1070919 | Inhibition of HCV genotype 1b NS5Bdelta21 RNA dependent RNA polymerase expressed in Escherichia coli JM109 (DE3) | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127). |
| AID758858 | Antiviral activity against Hepatitis C virus genotype 6 | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 | Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. |
| AID758857 | Antiviral activity against Hepatitis C virus genotype 5 | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 | Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. |
| AID1450605 | In vivo drug metabolism in human assessed as UGT-mediated deleobuvir acyl glucuronide metabolite formation in blood at 800 mg,po administered as single dose measured up to 12 hrs | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8). |
| AID758861 | Antiviral activity against Hepatitis C virus genotype 1b | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14 | Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. |
| AID1070912 | Inhibition of DNA polymerase-alpha (unknown origin) | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5 | Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (18)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 16.36
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.36) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 9 (50.00%) | 5.53% |
| Reviews | 1 (5.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (44.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||